76
Participants
Start Date
May 27, 2021
Primary Completion Date
October 26, 2023
Study Completion Date
June 10, 2025
XB2001 or Placebo
XB2001 is a True Human monoclonal antibody that blocks the biological activity of IL-1α with a high degree of affinity and specificity. IL-1⍺ is a key mediator of inflammatory responses and is implicated in the pathophysiology of various diseases, including cancer, cardiovascular and rheumatologic diseases. Ample evidence supports targeting IL-1⍺ to block pathological inflammatory processes associated with many diseases.
Montefiore Einstein Medical Center, The Bronx
Stony Brook Cancer Center, Stony Brook
UPMC Hillman Cancer Center, Pittsburgh
Virginia Cancer Specialists, Fairfax
Bon Secours St. Francis Cancer Center, Midlothian
Sarah Cannon - Florida Cancer Specialists, Lake Mary
Mt. Sinai Comprehensive Cancer Center, Miami Beach
Sarasota Memorial Hospital, Sarasota
Sarah Cannon - Tennessee Oncology, Nashville
Vanderbilt University, Nashville
University of Tennessee Medical Center Cancer Institute, Knoxville
Goshen Center for Cancer Care, Goshen
Revive Research - Sterling Heights, Sterling Heights
Barbara Ann Karmanos Cancer Institute, Detroit
Revive Research - Farmington Hills, Farmington Hills
St. Vincent Frontier Cancer Center, Billings
Alliance for Multispecialty Research, LLC, Merriam
Ochsner Clinic Foundation, New Orleans
Mary Crowley Cancer Research, Dallas
Grand Valley Oncology, Grand Junction
Community Cancer Trials of Utah, Ogden
Arizona Oncology Associates, Tucson
TOI Clinical Research, Cerritos
Disney Family Cancer Center at Providence St. Joseph Medical Center, Burbank
Hoag Memorial Hospital Presbyterian, Newport Beach
Providence St. Joseph Heritage - Fullerton, CA, Fullerton
Providence Portland, Portland
Summit Medical Group, Florham Park
XBiotech, Inc.
INDUSTRY